To observe the hemostatic efficacy of absorbable Surgiflo haemosatic matrix (trade name: Surgiflo) in endoscopic transsphenoidal pituitary adenomectomy.

A total of 40 patients performed endoscopic transsphenoidal pituitary adenomectomy in our hospital from January 2016 to June 2016, were recruited in our study; 16 had tumor cavity bleeding and 24 had cavernous sinus/intercavernous sinus bleeding; 10 patients had Grade 2 bleeding, 21 Grade 3 bleeding, 9 Grade 4 bleeding and none had Grade 5 bleeding. Surgiflo was used during the surgery. The clinical data and hemostatic efficacy of these patients were retrospectively analyzed.

In 40 patients, 36 patients achieved haemostasis only by Surgiflo and 4 by Surgiflo with electrocoaulation, bone wax, and hemostatic gauze. Patients with Grade 2, 3 and 4 bleeding had 1, 1.5 and 2.5 times of spray with Surgiflo. Postoperative CT revealed no bleeding. No advance reactions were recorded after one month of follow- up.

Surgiflo enjoys good, fast and safe haemostasis efficacy in endoscopic transsphenoidal pituitary adenomectomy, which is appropriate to tumor cavity bleeding, cavernous sinus/intercavernous sinus bleeding in transsphenoidal pituitary adenomectomy.

Endoscope; Pituitary adenoma; Haemostasis; Absorbable Surgiflo haemosatic matrix